Investigational Drug Development

Looking Forward

Fujifilm is conducting research to study the potential of new drugs to address unmet medical needs, focusing on cancer, infectious diseases and central nervous system diseases.

Fujifilm currently has clinical trials in the United States for cancer. These clinical trials are underway in collaboration with various institutions throughout the country.

*Avigan Tablet (favipiravir) has not been approved by the FDA for use in the USA


Investigational drug pipeline

Infectious diseases

Code Mode of Action Indication Region Stage Clinical Trial Information
T-705 RNA polymerase inhibitor Influenza Japan Approved
Severe fever with thrombocytopenia syndrome Japan Phase 3
T-4288 Bacterial protein synthesis inhibitor Otorhinolaryngologic infections Japan IND filing  
Respiratory tract infections Japan Phase 3


Code Mode of Action Monotherapy or Combination Indication Region Stage Collaboration Clinical Trial Information
FF-10502-01 DNA polymerase inhibitor   Advanced solid tumors U.S.A. Phase 2
FF-10832 Liposomal gemcitabine
(DNA replication polymerase inhibitor)
Monotherapy Advanced solid tumors
(Biliary tract cancer)
U.S.A. Phase 1
Combination with pembrolizumab1 Advanced solid tumors
(Non-small cell lung cancer and urothelial cancer)
U.S.A. Phase 2 *
FF-10850 Liposomal topotecan
(topoisomerase I inhibitor)
  Advanced solid tumors
(Ovarian cancer and Merkel cell carcinoma)
U.S.A. Phase 1

1Fujifilm Begins U.S. Clinical Phase 2a Study of FF-10832 in Combination with KEYTRUDA® (pembrolizumab, Merck & Co., Inc., Rahway, N.J., U.S.A.) for Patients with Advanced Solid Tumors | Fujifilm [United States]
*Merck & Co., Inc. is known as MSD outside the United States and Canada.


Code Mode of Action Indication Region Stage Clinical Trial Information
T-817MA Neuroprotectant, microglial modulator, neuroplasticity facilitator Alzheimer’s disease Japan
Phase 2
Functional recovery after stroke (Promoting the effect of rehabilitation) Japan Phase 2
The drug candidates created or tested by direct or indirect affiliates of FUJIFILM Holdings Corporation that are referred to on this page are still at development stage and not yet approved for commercialization. A future use and commercialization will be subject to the prior granting of a marketing authorization in the given territory and compliance with applicable laws.

Expanded access/Compassionate use

Currently, FUJIFILM Pharmaceuticals U.S.A., Inc. is not accepting expanded access/compassionate use requests.

Partnership Strategy

We are seeking the following partners:

  • Companies interested in clinical development and commercialization of Fujifilm’s pipeline drugs.